Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat.
European Journal of Pharmacology April 7, 1992 DOI: 10.1016/0014-2999(92)90094-k (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | S-amphetamine MBDB |
| Topics | MDMA |
| Citations | 35 |
| Key findings | S-MDMA injected into the nucleus accumbens produces locomotor hyperactivity that is not blocked by fluoxetine, indicating its action there is via catecholamine release rather than serotonin release. |
Abstract
This study examined the behavioral effects in rats of intracerebral administration of S(+)-3,4-methylenedioxymethamphetamine (S-MDMA) using an automated holeboard and open-field apparatus. Administration of S-MDMA into the nucleus accumbens septi produced locomotor hyperactivity. Although the stimulant effects of S-MDMA administered systemically are antagonized by fluoxetine pretreatment, the activating effects of S-MDMA administered into the nucleus accumbens were not antagonized by fluoxetine. A similar increase in locomotor activity was observed after S-amphetamine administration into the nucleus accumbens. In contrast, the selective 5-HT-releasing drug and S-MDMA congener N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) produces MDMA-like locomotor hyperactivity when administered systemically but did not alter locomotor activity when injected into the nucleus accumbens. These data indicate that S-MDMA actions in the nucleus accumbens are pharmacologically distinct from the primary effects of systemically administered S-MDMA. Behavioral effects of S-MDMA in the nucleus accumbens may result from the catecholamine-releasing properties that S-MDMA shares with S-amphetamine and not via the 5-HT-releasing properties that it shares with MBDB.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 11
- Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration British Journal of Pharmacology February 1, 1999
- Direct effects of 3,4‐methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphé nucleus slices Synapse April 27, 2000
- Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3-4, methylenedioxymethamphetamine (MDMA) in female SD rats European Journal of Pharmacology April 28, 2011
- Context‐dependent behavioural and neuronal sensitization in striatum to MDMA (ecstasy) administration in rats European Journal of Neuroscience July 1, 2006
- N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addiction Biology July 1, 2000
and 6 more in the library
Cites 10
- Can Drugs Be Used to Enhance the Psychotherapeutic Process? American Journal of Psychotherapy July 1, 1986
- Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes Journal of Medicinal Chemistry May 1, 1982
- Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology 1991
- Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. Journal of Pharmacology and Experimental Therapeutics August 1, 1990
- 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. European Journal of Pharmacology February 20, 1990
and 5 more in the library